In a case-control analysis with 3,731 postmenopausal breast cancer patients, Rennert G et al found a similar advantageous, but statistically underpowered, effect of oral bisphosphonates on overall survival in patients with ER positive as well as ER negative and Her-2 positive disease [40]. Here, ESR1 is linked to breast cancer.